Please ensure Javascript is enabled for purposes of website accessibility

Why ImmunoGen, Inc. Jumped Higher Today

By Brian Orelli, PhD - Updated Apr 20, 2017 at 4:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sentiment takes over the biotech's share price.

What happened

ImmunoGen (IMGN -0.28%) is up 15.6% at 3:35 p.m. EDT on no news. The stock price bump might be a carryover from yesterday's upgrade by Leerink Partners. Or maybe it's short-sellers buying to cover their shorts after yesterday's move. Or maybe it's just because it's a biotech and the sun came up today. Who knows?

So what

What is clear is that these short-term moves -- there was another unexplained one just last week -- have more to do with investor sentiment than ImmunoGen's fundamentals.

That said, investors are clearly hoping that the fundamentals will be different in the future, because valuations always revert to a company's ability to generate revenue and eventually profits. Investors wouldn't be willing to buy or hold at these higher prices if that weren't the case.

Doctor and patient having a conversation

Image source: Getty Images.

The next value-creating event will come in the form of data from a phase 1b/2 trial called FORWARD II, testing ImmunoGen's lead drug mirvetuximab soravtansine in combination with Avastin, carboplatin, Doxil, or Keytruda. Investors will also get to see pooled data from phase 1 trials testing mirvetuximab soravtansine in patients with ovarian cancer shortly. Both data sets are expected to be released this quarter.

The results aren't likely to be enough to get mirvetuximab soravtansine approved, but the data will help investors better interpret the likelihood that ImmunoGen's ongoing phase 3 trial will show the drug works better than placebo. That trial, dubbed FORWARD I, which is testing mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer, will be enough to gain marketing approval by the Food and Drug Administration if the trial is successful.

Now what

Long-term investors can ignore these short-term moves -- like the ones that go in the opposite direction -- as they're not important to the overall investment thesis. If mirvetuximab soravtansine helps ovarian cancer patients, today's move will have no influence on the valuation after the FORWARD I data are revealed.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ImmunoGen, Inc. Stock Quote
ImmunoGen, Inc.
IMGN
$3.57 (-0.28%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.